Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 20/20 | 1.00 |
| ▸ | CCR7 | P32248 | 4/20 | 0.78 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.72 |
| ▸ | CCR6 | P51684 | 3/20 | 0.72 |
| ▸ | CCR4 | P51679 | 1/20 | 0.72 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.65 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14895297 | 1.00 | CXCR1 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14894973 | 1.00 | CXCR1 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14895442 | 1.00 | CXCR1 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14895296 | 1.00 | CXCR1 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL12262779 | 0.88 | CXCR1 (0.93) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL12262746 | 0.88 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14904752 | 0.87 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14894600 | 0.86 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14895013 | 0.84 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 | |
| SCHEMBL14895104 | 0.84 | CXCR2 (1.00) | CXCR1CXCR2CCR7CXCR3CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | claimed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | claimed |
| EP-2771329-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-03-16 | — | — | EP | claimed |
| EP-2771329-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | Galderma Research & Development (FR) | 2014-09-03 | — | — | EP | claimed |
| WO-2013061004-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | claimed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | SYNTRIX BIOSYSTEMS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| US-9388149-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2771329-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-03-16 | — | — | EP | disclosed |
| EP-2771329-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-03-16 | — | — | EP | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2013061004-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | CXCR1 1/4885CXCR2 2/4885CCR7 26/4885 |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CXCR1 1/4885CXCR2 2/4885CCR7 23/4885 |
| US-20140296254-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCL11, CCR1 | CXCR1 11/4885CXCR2 9/4885CCR7 18/4885 |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | CXCR1, CXCR2, CXCR5 | CXCR1 1/4885CXCR2 2/4885CCR7 9/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR1 1/4885CXCR2 2/4885CCR7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.